Back to Search
Start Over
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
- Source :
- SCIENTIFIC REPORTS, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname, Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020), Scientific Reports
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 ± 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 ± 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p = 0.037 and p = 0.008, respectively). During a follow-up of 17.25 ± 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.
- Subjects :
- Adult
Male
medicine.medical_specialty
medicine.medical_treatment
Anti-Inflammatory Agents
lcsh:Medicine
Article
Inflammatory bowel disease
Medication Adherence
Persistence (computer science)
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
lcsh:Science
Adverse effect
Colectomy
030203 arthritis & rheumatology
Multidisciplinary
Tumor Necrosis Factor-alpha
business.industry
lcsh:R
Antibodies, Monoclonal
Middle Aged
medicine.disease
Ulcerative colitis
Golimumab
Clinical trial
Crohn's disease
Safety profile
Treatment Outcome
Spain
Colitis, Ulcerative
Female
lcsh:Q
030211 gastroenterology & hepatology
Observational study
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....fbf77fcd15d73c70dabb701e22d16ffc